ZMapp

ZMapp is an experimental treatment designed to combat Ebola virus disease. It consists of laboratory-made antibodies derived from immune cells that target and neutralize the Ebola virus, helping the immune system fight the infection. Administered through an intravenous (IV) infusion, ZMapp was used during Ebola outbreaks to provide hope before fully approved medications were available. While it showed promise in early trials, its effectiveness varies, and it is considered an investigational therapy. ZMapp represents a targeted biological approach aiming to improve survival rates in severe Ebola cases.